Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa
- PMID: 31308545
- PMCID: PMC6779477
- DOI: 10.1038/s41588-019-0439-2
Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa
Abstract
Characterized primarily by a low body-mass index, anorexia nervosa is a complex and serious illness1, affecting 0.9-4% of women and 0.3% of men2-4, with twin-based heritability estimates of 50-60%5. Mortality rates are higher than those in other psychiatric disorders6, and outcomes are unacceptably poor7. Here we combine data from the Anorexia Nervosa Genetics Initiative (ANGI)8,9 and the Eating Disorders Working Group of the Psychiatric Genomics Consortium (PGC-ED) and conduct a genome-wide association study of 16,992 cases of anorexia nervosa and 55,525 controls, identifying eight significant loci. The genetic architecture of anorexia nervosa mirrors its clinical presentation, showing significant genetic correlations with psychiatric disorders, physical activity, and metabolic (including glycemic), lipid and anthropometric traits, independent of the effects of common variants associated with body-mass index. These results further encourage a reconceptualization of anorexia nervosa as a metabo-psychiatric disorder. Elucidating the metabolic component is a critical direction for future research, and paying attention to both psychiatric and metabolic components may be key to improving outcomes.
Conflict of interest statement
Competing interests
The authors report the following potential competing interests. O.A.A. received a speaker’s honorarium from Lundbeck. G.B. received grant funding and consultancy fees in preclinical genetics from Eli Lilly, consultancy fees from Otsuka and has received honoraria from Illumina. C.M.B. is a grant recipient from Shire Pharmaceuticals and served on Shire Scientific Advisory Board; she receives author royalties from Pearson. D.D. served as a speaker and on advisory boards, and has received consultancy fees for participation in research from various pharmaceutical industry companies including: AstraZeneca, Boehringer, Bristol Myers Squibb, Eli Lilly, Genesis Pharma, GlaxoSmithKline, Janssen, Lundbeck, Organon, Sanofi, UniPharma, and Wyeth; he has received unrestricted grants from Lilly and AstraZeneca as director of the Sleep Research Unit of Eginition Hospital (National and Kapodistrian University of Athens, Greece). J.I.H. has received grant support from Shire and Sunovion, and has received consulting fees from DiaMentis, Shire, and Sunovion. A.S.K. is a member of the Shire Canadian BED Advisory Board and is on the steering committee for the Shire B/educated Educational Symposium: June 15-16, 2018. J.L.K. served as an unpaid member of the scientific advisory board of AssurexHealth Inc. M.L. declares that, over the past 36 months, he has received lecture honoraria from Lundbeck and served as scientific consultant for EPID Research Oy. No other equity ownership, profit-sharing agreements, royalties, or patent. P.F.S. is on the Lundbeck advisory committee and is a Lundbeck grant recipient; he has served on the scientific advisory board for Pfizer, has received a consultation fee from Element Genomics, and a speaker reimbursement fee from Roche. J.T. has received an honorarium for participation in an EAP meeting and has received royalties from several books from Routledge, Wiley, and Oxford University press. T.W. has acted as a lecturer and scientific advisor to H. Lundbeck A/S. All other authors have no conflicts of interest to disclose.
Figures


References
-
- Keski-Rahkonen A & Mustelin L Epidemiology of eating disorders in Europe: prevalence, incidence, comorbidity, course, consequences, and risk factors. Curr. Opin. Psychiatry 29, 340–345 (2016). - PubMed
Publication types
MeSH terms
Grants and funding
- R21 MH104831/MH/NIMH NIH HHS/United States
- K01 AA025113/AA/NIAAA NIH HHS/United States
- U01 MH109536/MH/NIMH NIH HHS/United States
- U01 MH109514/MH/NIMH NIH HHS/United States
- U01 HG006830/HG/NHGRI NIH HHS/United States
- K01 MH109782/MH/NIMH NIH HHS/United States
- K01 MH106675/MH/NIMH NIH HHS/United States
- R01 MH106611/MH/NIMH NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- K01 MH109772/MH/NIMH NIH HHS/United States
- R01 MH092793/MH/NIMH NIH HHS/United States
- U01 MH109528/MH/NIMH NIH HHS/United States
- R21 MH115397/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases